- Conditions
- Pseudofolliculitis Barbae
- Interventions
- Eflornithine Topical, Placebo Eflornithine Topical
- Drug
- Lead sponsor
- Walter Reed National Military Medical Center
- Federal
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 3,497
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Inflammation, C-reactive Protein, Exercise Capacity
- Interventions
- Active Fruit Juice Intervention, Control Fruit Juice Intervention
- Other
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diminished Ovarian Reserve, IVF, G-CSF, Granulocyte Colony Stimulating Factor
- Interventions
- Neupogen 300 μg subcutaneous injection, Subcutaneous injections of a saline solution
- Drug · Other
- Lead sponsor
- Center for Human Reproduction
- Other
- Eligibility
- 35 Years to 44 Years · Female only
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Head and Neck Cancer
- Interventions
- Medpulser electroporation with Bleomycin, Tumor surgical excision
- Combination Product · Procedure
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Enterovirus Infection
- Interventions
- EV68-228-N, Placebo for EV68-228-N
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Nashville, Tennessee
- Conditions
- Childhood Obesity
- Interventions
- TRE Group
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Menkes Disease
- Interventions
- Droxidopa Oral Product, Placebo Control
- Drug · Other
- Lead sponsor
- Stephen G. Kaler
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Food Intolerance
- Interventions
- Whey Protein Concentrate, Pea Protein Isolate, Rice Protein Concentrate, Hemp Protein
- Dietary Supplement
- Lead sponsor
- University of the Incarnate Word
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity
- Interventions
- Byetta 5Mcg Pen Injection
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Years to 21 Years · Female only
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Cancer of the Breast, Chemotherapy-induced Neuropathy
- Interventions
- Tango
- Behavioral
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Columbus, Ohio
- Conditions
- Aging
- Interventions
- Probiotic capsule and Fiber Sachet, Probiotic capsule and Placebo sachet, Placebo capsule and Fiber Sachet, Placebo capsule and Placebo sachet
- Dietary Supplement
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 65 Years and older · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Ocala, Florida
- Conditions
- Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- recombinant interferon alfa, rituximab
- Biological
- Lead sponsor
- Hoag Memorial Hospital Presbyterian
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 1999
- U.S. locations
- 3
- States / cities
- Newport Beach, California • Knoxville, Tennessee • Bryan, Texas
- Conditions
- Hypertension
- Interventions
- Valsartan/Hydrochlorothiazide
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 648 participants
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Interventions
- Interferon Beta-1a
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 9 more
- Conditions
- Labor; Forced or Induced, Affecting Fetus or Newborn
- Interventions
- Oxytocin, Transcervical Foley catheter
- Drug · Device
- Lead sponsor
- Christiana Care Health Services
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 323 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- Newark, Delaware • Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,939 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 1454
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 888 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- DWN12088, Placebo
- Drug
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 20
- States / cities
- Mesa, Arizona • Phoenix, Arizona • San Francisco, California + 14 more
- Conditions
- Traumatic Brain Injury
- Interventions
- Recombinant human Growth Hormone, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 3
- States / cities
- Bakersfield, California • Dallas, Texas
- Conditions
- Herpes Labialis
- Interventions
- onabotulinumtoxinA, Bacteriostatic normal saline
- Drug · Other
- Lead sponsor
- DeNova Research
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Ligelizumab, Omalizumab, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,078 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 29 more
- Conditions
- Abortion, Induced, Pain
- Interventions
- Paracervical block, Intracervical, Buffered Lidocaine, vasopressin, sodium bicarbonate
- Procedure · Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Multiple Myeloma
- Interventions
- Velcade, Melphalan, Prednisone, Daratumumab IV, Dexamethasone, Daratumumab SC
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 706 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 10
- States / cities
- California City, California • Corona, California • Fountain Valley, California + 7 more
- Conditions
- Charcot-Marie-Tooth Disease
- Interventions
- ACE-083, Placebo
- Drug
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 16
- States / cities
- Orange, California • Aurora, Colorado • Gainesville, Florida + 13 more
- Conditions
- Insulin Resistance, Hyperinsulinemia, Obesity, Healthy
- Interventions
- Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min, Dextrose 20 % in Water, Glucagon, 0-0.5 ng/kg/min
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York